Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/26361997v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1dac0d9org.highwire.dtl.DTLVardef@aaf8f2org.highwire.dtl.DTLVardef@be10a1org.highwire.dtl.DTLVardef@35c7be_HPS_FORMAT_FIGEXP M_FIG C_FIG BACKGROUNDThe effect of neurovascular health on cardiovascular outcomes is not well-known. Cerebral small vessel disease (CSVD) signals subclinical vascular brain injury and its quantification may serve as a tool to stratify risk in healthy individuals. Studying the relations of CSVD to cardiovascular events and mortality could aid in targeted preventive efforts. METHODSWe included Framingham Heart Study participants free of diagnosed stroke and dementia. CSVD was assessed on brain MRI--considering covert infarcts, cerebral microbleeds, cortical superficial siderosis, high perivascular space burden, and extensive white matter hyperintensities--with 1 point assigned for each marker, to categorize CSVD scores as 0, 1, or 2+. We used a composite outcome and three components: stroke, myocardial infarction, and mortality. Cox regression analysis was used with models adjusted for age, sex, cohort, MRI-exam cycle time interval, and vascular risk factors. RESULTSIn our study, 31% of our 3263 participants (mean age 58.0 years [SD: 13.4], 54% women) had a CSVD score greater than 0, and those with higher scores were generally older and had higher prevalence of vascular risk factors. Over a median follow-up of 8.4 years, 454 participants (13.9%) experienced at least one outcome, with mortality being the most common. Increasing CSVD burden was associated with higher incidence rates of the composite outcome. Compared with participants with CSVD score 0, those with scores of 1 and 2 had significantly higher risk of any event (HR 1.48, 95% CI 1.19-1.85; HR 1.52, 95% CI 1.17-1.97 respectively). CSVD burden showed a dose-response relationship with all-cause mortality and was associated with increased stroke risk, while no significant association with MI was observed. CONCLUSIONHigher subclinical CSVD burden is independently associated with increased risk of adverse cardiovascular events and mortality in community-dwelling individuals. CSVD detected on brain MRI may serve as a valuable imaging biomarker for risk stratification and early prevention of life-threatening outcomes. Indexing Terms: Stroke, Mortality, Myocardial Infarction, Cerebral Small Vessel Disease, Vascular Disease, Brain MRI

What this study adds

Evidence grade: Moderate

The record lists 3,263 participants. It concerns vascular risk prediction and does not test any treatment, cure or prevention for Alzheimer's disease. Reported effect size: 13.9%; HR 1.48; HR 1.52.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Manchanda, R., Pinheiro, A., Aparicio, H. J., Lioutas, V.-A., Beiser, A. S., Sisto, J., et al. (2026). Cerebral Small Vessel Disease and Risk of Cardiovascular Events and All-Cause Mortality: The Framingham Heart Study. medRxiv (preprint). https://doi.org/10.64898/2026.09.01.26361997

Vancouver

Manchanda R, Pinheiro A, Aparicio HJ, Lioutas V.-A, Beiser AS, Sisto J, et al. Cerebral Small Vessel Disease and Risk of Cardiovascular Events and All-Cause Mortality: The Framingham Heart Study. medRxiv (preprint). 2026. doi:10.64898/2026.09.01.26361997.

BibTeX

@article{manchanda2026-68b7c246,
  author  = {Manchanda, R. and Pinheiro, A. and Aparicio, H. J. and Lioutas, V.-A. and Beiser, A. S. and Sisto, J. and Ekenze, O. and Benjamin and others},
  title   = {{Cerebral Small Vessel Disease and Risk of Cardiovascular Events and All-Cause Mortality: The Framingham Heart Study}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.01.26361997},
  url     = {https://doi.org/10.64898/2026.09.01.26361997}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that a higher burden of cerebral small vessel disease markers on brain MRI was linked to higher risk of cardiovascular events and all-cause mortality, with a dose-response relationship for mortality and increased stroke risk but no significant association with heart attack. It concerns vascular risk prediction and does not test any treatment, cure or prevention for Alzheimer's disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 32 of the 94 points it could be judged on, which is 34 of 100. Raw total 34 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 34 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 32 of the 94 points we could judge it on, which is 34 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 3,263 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Jose Rafael Romero: h-index 68 (OpenAlex, whole career)
Institution's track record 1 / 3 Boston University: institution h-index 1,456 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 32 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 94 points we could judge it on is 34 out of 100.
Total 34 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Prevention and risk from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →